---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-031041"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:48:56.956947+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin Q2 net loss $7.6M ($0.12/sh); secures $10M credit line from chairman

## Summary
- Net loss applicable to common stockholders of $7.6M ($0.12 per share) vs $12.4M ($0.20) in Q2 2024.
- R&D expenses fell to $3.3M from $9.8M due to NAVIGATE trial completion in Q1 2025.
- Cash and equivalents $13.8M at June 30; $10M line of credit from chairman closed July 8.
- Company expects sufficient funding to operate through June 30, 2026.
- NAVIGATE data at EASL showed belapectin reduced liver stiffness progression over 18 months.

## SEC filing metadata
- accession: 0001140361-25-031041
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/0001140361-25-031041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/ef20053791_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-031041
- JSON: https://secwatch.observer/filing/0001140361-25-031041.json
- Plain text: https://secwatch.observer/filing/0001140361-25-031041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.